Cambridge Cognition Holdings PLC GBP1.3 million contract for a schizophrenia trial (8687T)
30 Marzo 2021 - 12:00AM
UK Regulatory
TIDMCOG
RNS Number : 8687T
Cambridge Cognition Holdings PLC
30 March 2021
Cambridge Cognition Holdings Plc
(" Cambridge Cognition" or the "Company")
Cambridge Cognition wins GBP1.3 million cognitive assessment
contract for a schizophrenia trial
Cambridge Cognition (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce
that it has won a GBP1.3 million contract as the cognitive
assessment partner for a schizophrenia trial. Revenue from the
contract is expected to be booked over the next three years. This
is the fourth schizophrenia trial Cambridge Cognition has secured
with this pharmaceutical client in seven months. The first three
were announced by the Company on 1 September 2020 in a GBP2 million
contract.
Cognitive impairment is a core feature of schizophrenia, with
deficits frequently observed in memory, attention and executive
functions. Impressed by the high degree of sensitivity CANTAB(TM)
cognitive assessments demonstrate in measuring these distinct
processes and the quality of service the Company delivers,
Cambridge Cognition has been named as the cognitive assessment
provider for the fourth trial in the series.
Matthew Stork, Chief Executive Officer of Cambridge Cognition,
said:
"Schizophrenia affects more than 20 million people worldwide and
we are pleased to be strengthening our relationship with a company
that recognises the importance of sensitive and accurate cognitive
assessment in developing effective therapeutics for the disorder.
This quick succession of unusually large contracts with the same
pharmaceutical company is a testament to the excellent customer
experience and high-quality products Cambridge Cognition
delivers."
For further information, contact:
Cambridge Cognition Holdings PLC Tel: 012 2381 0700
Matthew Stork, Chief Executive Officer press@camcog.com
Michael Holton, Chief Financial Officer
finnCap Ltd (NOMAD and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and IR) Tel: 020 3934 6630
Tim Metcalfe / Graham Herring / Zach Cohen
Notes to Editors
About Cambridge Cognition
Cambridge Cognition is a technology company developing digital
health products to better understand, detect and treat conditions
affecting brain health. The Company's software products assess
cognitive health in patients worldwide to improve clinical trial
outcomes, identify and stratify patients early and improve global
efficiency in pharmaceutical and healthcare industries.
For further information visit www.cambridgecognition.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
CNTBLGDXRSDDGBC
(END) Dow Jones Newswires
March 30, 2021 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024